STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

133 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-09-01

Study Completion Date

2015-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to perform exploratory analyses to evaluate rates of functional and structural change in glaucoma, to identify predictors of rapid progression in patients with glaucoma and to identify possible genetic factors and biomarkers associated with the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic Innovations in Glaucoma Study

NCT00221897

Primary Open Angle Glaucoma Myopia

RECRUITING

Prospective, Open Label Study to Assess 24hs IOP Recorded With Triggerfish® in Patients With OAG Before and After DSCI

NCT05876936

Open Angle Glaucoma

TERMINATED NA

IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy

NCT01766947

Primary Open Angle Glaucoma

WITHDRAWN NA

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

NCT01828255

Primary Open-angle Glaucoma (POAG) Patient

TERMINATED NA

Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy

NCT02406833

Primary Open Angle Glaucoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES

To identify and combine a set of predictors (i.e. by statistical modeling, machine learning classifiers or neural networks) to predict progression in glaucoma patients To determine how to most sensitively and specifically determine progression for a trial of a potential neuroprotective agent.

SECONDARY OBJECTIVES

To evaluate genetic and other potential biomarkers associated with progression in glaucoma.

To evaluate tests currently used on glaucoma patients to better predict which ones are most sensitive to detect disease progression and measure rates of change.

To assess progression by structural and functional tests:

* Optic disc stereophotographs
* Cirrus OCT
* RTVue OCT
* Standard Automated Perimetry (SAP)
* Frequency Doubling Technology Matrix

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary Open Angle Glaucoma

• Group A (diagnosis of primary open-angle glaucoma or pseudo-exfoliative glaucoma) - subjects with documented disease progression in the past and high IOP (IOP above target), disc hemorrhage, family history of glaucoma-related vision loss or thin central cornea (\<510um),

* Progression is confirmed with repeatable abnormal standard automated perimetry (SAP) or progressive glaucomatous optic neuropathy
* For patients that have had previous glaucoma surgery, they can be included if they have had documented glaucomatous progression post-surgery
* Best corrected visual acuity of 20/40 or better at enrollment

No interventions assigned to this group

Healthy Individuals

• Group B (healthy controls)- healthy subjects without any ophthalmic disease and an IOP \< 22mmHg

o Normal appearing optic disc and no evidence of optic disc damage

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects will be eligible if the following criteria are met:

* Group A (diagnosis of primary open-angle glaucoma or pseudo-exfoliative glaucoma) - subjects with documented disease progression in the past 3 years and high IOP (IOP above target), disc hemorrhage (within 3 years), family history of glaucoma-related vision loss or thin central cornea (\<510um),

* Progression is confirmed with repeatable abnormal standard automated perimetry (SAP) or progressive glaucomatous optic neuropathy
* For patients that have had previous glaucoma surgery, they can be included if they have had documented glaucomatous progression post-surgery
* Best corrected visual acuity of 20/40 or better at enrollment
* Group B (healthy controls)- healthy subjects without any ophthalmic disease and an IOP \< 22mmHg

o Normal appearing optic disc and no evidence of optic disc damage
* Ability to provide written informed consent for participation in this study

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from this study:

* Subjects with an ocular disease other than glaucoma
* Subjects participating in a long-term interventional clinical trial
* Subjects with any other medical condition which would prohibit them from making all study visits within the 24 months
* Glaucoma patients who have not demonstrated disease progression in the past 3 years
* Patients with diagnosis of pigmentary dispersion syndrome/glaucoma
* Patients that have had glaucoma surgery and have IOP ≤ 12 mm Hg
* Patients with advanced glaucoma with MD ≤ -20 dB
* Patients with a history of LASIK surgery
* Patients with myopia \> -6.0 diopters.
* Patients with hyperopia \>+6.0 diopters.
* In the investigator's opinion, any patient that cannot satisfactorily complete all of the structural and functional testing included in the protocol (investigator determined)
* Unable to perform reliable VF testing (Fixation losses 33% or less, false negative rate 33% or less and false positive rate of 15% or less) at the time of study entry
* In the investigator's opinion, any patient with an ocular disease that could impact study assessments
* Patients with cataracts in which surgery is planned or anticipated within the next 3 months.
* Patients with narrow angles in which laser iridotomy is planned or anticipated within the next 3 months.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes